Hepalys Pharma
Latest round
- Series A
Last raised
- Sep 2023
Total raised
- $11M
Investors
- 1
About Hepalys Pharma
Based in Tokyo, Japan, and founded in 2021, Hepalys Pharma, Inc. operates as a developer of lanifibranor, a drug candidate for the treatment of non-alcoholic fatty liver disease. In September 2023, Hepalys Pharma, Inc. As of 2023, Hepalys Pharma, Inc. is currently operating in stealth mode. The company develops and commercialize Inventiva's proprietary drug candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea.
Who invested in Hepalys Pharma
1 investor across 1 round
See all investors in Hepalys Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 29, 2023
Amount
$11M
Investors
Questions about Hepalys Pharma
Who invested in Hepalys Pharma?
Hepalys Pharma has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hepalys Pharma raised?
Hepalys Pharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hepalys Pharma last raise money?
Hepalys Pharma's most recent round on record is a Series A, in Sep 2023.
What does Hepalys Pharma do?
Based in Tokyo, Japan, and founded in 2021, Hepalys Pharma, Inc.
Where is Hepalys Pharma headquartered?
Hepalys Pharma is headquartered in Tokyo, Japan.
Which VCs invest in companies like Hepalys Pharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Hepalys Pharma's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Hepalys Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.